Active Ingredient History
Axitinib (trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. It was approved by the U.S. Food and Drug Administration. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adrenal Cortex Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Neoplasms (Phase 1/Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 1)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Pancreatic Ductal (Phase 3)
Carcinoma, Transitional Cell (Phase 3)
Colorectal Neoplasms (Phase 2)
Drugs, Investigational (Phase 2)
Endometrial Neoplasms (Phase 2)
Endometriosis (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1)
Healthy Volunteers (Phase 1)
Hepatic Insufficiency (Phase 1)
Kidney Neoplasms (Phase 3)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Macular Degeneration (Phase 1)
Melanoma (Phase 3)
Mesothelioma, Malignant (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neuroendocrine Tumors (Phase 2)
Neurofibromatosis 2 (Phase 2)
Neuroma, Acoustic (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 2)
Pheochromocytoma (Phase 2)
Prostatic Neoplasms (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Alveolar Soft Part (Phase 2)
Sarcoma, Clear Cell (Phase 2)
Skin Neoplasms (Phase 2)
Solitary Fibrous Tumors (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 1)
Thyroid Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
